Hims & Hers Health Inc Stock Price, News & Analysis

Hims & Hers (NYSE: HIMS) will report third quarter 2025 financial results after market close on Monday, November 3, 2025. A live conference call to discuss results is scheduled for 5:00 p.m. ET the same day.

U.S. dial-in is (888) 510-2630, international dial-in is (646) 960-0137, conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and archived for one year.

Hims & Hers (NYSE: HIMS) published a white paper on clinical quality, safety, and customer experience in telehealth on October 9, 2025. Key survey and operational findings show high patient confidence and low reported side effects across treatment categories.

Highlights include 94% of ~2,400 surveyed customers rating telehealth care as equal to or better than prior in-person care; 91% found intake easy; 83% reported increased confidence; and low messaging-reported side-effect rates for major categories (e.g., 0.08% for 418,000+ GLP-1 weight loss customers, 0.01%–0.08% for sexual and mental health).

The paper describes continuous clinical review by a team with >100 years combined experience and pharmacy controls aligned to FDA, USP, and state standards.

Hims & Hers Health (NYSE:HIMS) announced a major expansion into testosterone treatments through an exclusive collaboration with Marius Pharmaceuticals. The company will launch KYZATREX®, an FDA-approved oral testosterone medication, in 2026, shown to restore testosterone levels in up to 96% of men.

The platform is immediately launching personalized treatment options including compounded enclomiphene and a dual-action treatment combining enclomiphene with tadalafil. The company will also introduce injectable testosterone treatments in 2026. The initiative aims to address the estimated 20 million men in the U.S. affected by low testosterone, offering simplified access through at-home blood testing and licensed provider consultation.

Hims & Hers Health (NYSE:HIMS) reported strong Q2 2025 financial results, with revenue reaching $544.8 million, up 73% year-over-year. The company achieved net income of $42.5 million and Adjusted EBITDA of $82.2 million.

Subscriber base grew to over 2.4 million, representing a 31% increase year-over-year, while monthly online revenue per subscriber improved by 30% to $74. The company maintained its full-year 2025 guidance, projecting revenue between $2.3-2.4 billion and Adjusted EBITDA of $295-335 million.

For Q3 2025, HIMS expects revenue of $570-590 million and Adjusted EBITDA of $60-70 million. The company plans to expand into new specialties and enhance its personalization infrastructure, lab testing capabilities, and international presence.

Hims & Hers Health (NYSE: HIMS) has released compelling data demonstrating the success of its personalized weight loss program featuring GLP-1 treatments. The analysis revealed that customers lost an average of 20.9 pounds (10.3% of initial body weight) within six months, with a remarkable 75% retention rate during the treatment period.

The company's holistic approach combines personalized GLP-1 dosing with 24/7 care team access and comprehensive wellness support. Key metrics include a low 10.3% side effect rate, with only 4.5% reporting intolerable effects. The platform facilitated over 6.7 million customer-care team messages, with 75% of responses delivered within 5 hours. Notably, 97% of customers reported improved overall health, and 73% preferred Hims & Hers' digital health experience over alternatives.

Hims & Hers Health (NYSE: HIMS), the leading health and wellness platform, has scheduled its second quarter 2025 financial results announcement for August 4, 2025, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results.

Additionally, management will participate in the Canaccord Genuity's 45th Annual Growth Conference on August 13, 2025 in Boston.

Hims & Hers Health (NYSE: HIMS) has announced plans to expand into Canada in 2026, coinciding with the first-ever availability of generic semaglutide globally. This strategic expansion follows the company's recent acquisition of European digital health platform ZAVA.

The expansion aims to address a significant market need, as nearly two-thirds of Canadian adults are overweight or living with obesity. The company plans to offer affordable weight loss treatment through its digital platform, featuring 24/7 access to licensed providers and personalized care plans. Currently, branded semaglutide in Canada costs over C$200 monthly, but generic versions are expected to be available at a significant discount.

Hims & Hers Health (NYSE: HIMS) has announced plans to acquire ZAVA, a leading European digital health platform, marking a significant expansion into European markets including the UK, Germany, France, and Ireland. ZAVA currently serves over 1.3 million active customers and completed nearly 2.3 million consultations in 2024. The acquisition, expected to close in H2 2025, will be funded entirely in cash from Hims & Hers' balance sheet. The company plans to establish its branded presence across these markets, offering personalized healthcare services in local languages across dermatology, weight loss, sexual health, and mental health. The deal is expected to be accretive by 2026, with ZAVA's established infrastructure and medical expertise complementing Hims & Hers' proven brand and healthcare platform.

Hims & Hers Health (NYSE: HIMS) has launched a new pricing initiative for Wegovy®, offering eligible new customers access to the prescription-only weight loss treatment at $549 per month for 6 months through a limited-time offer. The program includes access to the company's comprehensive weight loss approach, featuring technology-driven solutions and holistic care options.

CEO Andrew Dudum emphasized the company's commitment to increasing healthcare accessibility. The platform continues to provide various weight loss solutions, including medications, oral kits, protein supplements, nutrition kits, and clinically-backed care plans, tailored to customers' needs, goals, and eligibility.